Findings

What do systematic reviews say?

4 questions · 4 findings · 4 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 50%GRADE not reported 1 · 25%Very low 0 · 0%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Quality of life · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma

The review found no eligible studies for this question.

1 finding from 1 review

Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Plerixafor vs placebo

Quality of life · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

The review found no eligible studies for this question.

1 finding from 1 review

Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bortezomib vs no bortezomib

Health‐related quality of life · All patients with a diagnosis of multiple myeloma

1 finding from 1 review

Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 717 participants
GRADE not reported

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with newly diagnosed multiple myeloma ineligible for transplant

1 finding from 1 review

Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1096 participants
Low